Boric Acid Proteasome Inhibitor Structure for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing boric acid-based proteasome inhibitors exhibit unsatisfactory oral bioavailability, limiting their use in oral treatments for diseases such as malignant and autoimmune diseases.
Innovation Solution
Development of novel boric acid-based proteasome inhibitors with specific structural variations, including various substituents and stereo configurations, to enhance oral bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If boric acid-based proteasome inhibitors are used, then proteasome inhibitory activity is improved, but oral bioavailability deteriorates
Solution Approach 1:
The patent modifies the molecular structure of boric acid-based proteasome inhibitors by changing chemical parameters such as introducing specific substituents (aryl groups, heteroaryl groups, cycloalkyl groups) at defined positions (R1, R2, R3) to optimize both proteasome inhibitory activity and oral bioavailability. This structural parameter optimization resolves the contradiction between activity and bioavailability.
Solution Approach 2:
The patent creates composite molecular structures by combining boric acid core with various functional groups and substituents (aryl, heteroaryl, cycloalkyl, etc.) to form novel compounds that simultaneously achieve high proteasome inhibitory activity and improved oral bioavailability, effectively resolving the contradiction through structural composite design.
2Reliability
If existing boric acid-based proteasome inhibitors are used, then proteasome activity is inhibited, but oral administration effectiveness deteriorates
Solution Approach 1:
The patent optimizes the pharmacokinetic parameters of boric acid-based inhibitors by modifying molecular weight, lipophilicity, and structural flexibility through substituent selection, thereby improving oral administration effectiveness while maintaining proteasome inhibition reliability.
Solution Approach 2:
The patent introduces specific functional groups and substituents at particular positions (R1, R2, R3) of the boric acid-based molecule to locally optimize properties such as membrane permeability and metabolic stability, thereby improving oral administration effectiveness without compromising overall proteasome inhibition.
Data Source
AI summary
The present disclosure provides a boric acid proteasome inhibitor compound represented by formula I and use thereof as a proteasome inhibitor.